LOGIN  |  REGISTER
Assertio
Cue Biopharma

Electromed to Present at the Investor Summit Virtual on June 10, 2025

June 09, 2025 | Last Trade: US$18.93 0.24 -1.25

NEW PRAGUE, MN / ACCESS Newswire / June 9, 2025 / Electromed, Inc. announced that Jim Cunniff, President and Chief Executive Officer, will be presenting at the Investor Summit Virtual taking place on June 10.

About Electromed, Inc.

Electromed (NYSE American: ELMD) is a profitable and growing medical device company that develops, manufactures, markets and sells innovative High Frequency Chest Wall Oscillation (HFCWO) airway clearance products, primarily for use in the home setting. Our flagship product, the SmartVest® Airway Clearance System, is a differentiated device designed for patient comfort and ease of use. We believe the domestic market for HFCWO devices is largely untapped, with fewer than 15% of the approximately 824,000 patients diagnosed with bronchiectasis in the US currently using this non-invasive therapy.

Event: Q2 Investor Summit
Presentation Time: June 10, 11:30 AM ET
Location: WEBCAST LINK

Conference Overview and Structure

The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.

This quarter's event is focused on MicroCap companies who are undervalued, have a catalyst, and are undervalued.

Registration for Investors

To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.

Sponsors:

  • AccessNewswire

  • PCG Advisory

  • QuoteMedia

  • AGP

  • MZ Group

News Compliments of ACCESSWIRE

For More Information

Please visit: https://investorsummitgroup.com/

Or, contact This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page